J1

9lr2637 CF HB 574

By: **Senators Pugh, Frosh, Jones, and Lenett** Introduced and read first time: February 6, 2009 Assigned to: Finance

A BILL ENTITLED

1 AN ACT concerning

Prescription Drugs - Evidence-Based Prescriber Education and Outreach Program

4 FOR the purpose of establishing an Evidence-Based Prescriber Education and 5 Outreach Program in the Department of Health and Mental Hygiene; 6 establishing the purpose of the Program; requiring the Department, beginning 7 on a certain date in consultation with certain health occupation boards and 8 subject to certain availability, to work with the University of Maryland School 9 of Pharmacy to develop, implement, and promote the Program; authorizing the 10 Department to contract with the School to administer the Program; requiring 11 the Program to provide certain health care professionals with certain information and education; authorizing the Program to provide the information 12 and education to other health care professionals under certain circumstances; 13 14 establishing requirements for the informational and educational materials used in the Program; requiring the Department, working with the School, to make 1516 certain determinations for individuals conducting outreach and education 17sessions; authorizing the Department to adopt certain regulations; establishing 18 an Evidence-Based Prescriber Education and Outreach Program Fund; 19 establishing the purpose of and requirements for the Fund; providing that the 20Fund consists of certain fees and certain other money; providing that the Fund 21may be used only for certain purposes; requiring the State Treasurer to invest 22the money of the Fund in a certain manner and to credit certain earnings to the 23General Fund of the State; providing that expenditures from the Fund may be 24made only in accordance with the State budget; requiring as of a certain date and annually thereafter certain pharmaceutical manufacturers and labelers to 25pay a certain fee to the Department; authorizing the Department to reduce the 26 27fee for certain pharmaceutical manufacturers and labelers; requiring the 28Department to deposit all fees collected in the Fund; defining certain terms; and 29 generally relating to an Evidence-Based Prescriber Education and Outreach 30 Program.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW. [Brackets] indicate matter deleted from existing law.



$ \begin{array}{c} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ \end{array} $	BY adding to Article – Health – General Section 21–2B–01 through 21–2B–03 to be under the new subtitle "Subtitle 2B. Evidence–Based Prescriber Education and Outreach Program" Annotated Code of Maryland (2005 Replacement Volume and 2008 Supplement) SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:
9	Article – Health – General
10	SUBTITLE 2B. EVIDENCE-BASED PRESCRIBER EDUCATION AND OUTREACH
11	PROGRAM.
12	21–2B–01.
$\begin{array}{c} 13\\14\end{array}$	(A) (1) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.
15	(2) "Fund" means the Evidence-Based Prescriber
16	Education and Outreach Program Fund.
17	(3) "LABELER" MEANS A PERSON THAT:
18	(I) RECEIVES PRESCRIPTION DRUGS OR BIOLOGICAL
19	PRODUCTS FROM A MANUFACTURER OR WHOLESALE DISTRIBUTOR;
20	(II) REPACKAGES THE PRESCRIPTION DRUGS OR
21	BIOLOGICAL PRODUCTS FOR LATER RESALE; AND
22	(III) HAS A LABELER CODE FROM THE FEDERAL FOOD AND
23	DRUG ADMINISTRATION UNDER § 207.20 OF TITLE 21 OF THE CODE OF
24	FEDERAL REGULATIONS.
25	(4) "PHARMACEUTICAL MANUFACTURER" MEANS A
26	MANUFACTURER, OR AN AFFILIATE OF A MANUFACTURER, OF PRESCRIPTION
27	DRUGS OR BIOLOGICAL PRODUCTS.
28	(5) "PROGRAM" MEANS THE EVIDENCE-BASED PRESCRIBER
29	EDUCATION AND OUTREACH PROGRAM.
$30 \\ 31 \\ 32$	(6) (I) "STATE HEALTH CARE PROGRAM" MEANS A PROGRAM OR FACILITY SERVING INDIVIDUALS FOR WHOM THE STATE PURCHASES PRESCRIPTION DRUGS OR PHARMACEUTICAL SERVICES.

 $\mathbf{2}$

1 (II) "STATE HEALTH CARE PROGRAM" INCLUDES THE 2 MEDICAL ASSISTANCE PROGRAM, THE STATE EMPLOYEE AND RETIREE 3 HEALTH AND WELFARE BENEFITS PROGRAM, STATE HOSPITALS, AND 4 CORRECTIONAL FACILITIES.

5 (B) THERE IS AN EVIDENCE-BASED PRESCRIBER EDUCATION AND 6 OUTREACH PROGRAM IN THE DEPARTMENT.

7 (C) THE PURPOSE OF THE PROGRAM IS TO IMPROVE HEALTH 8 OUTCOMES AND REDUCE UNNECESSARY COSTS BY ENSURING THAT HEALTH 9 CARE PROFESSIONALS HAVE BALANCED AND UNBIASED EVIDENCE-BASED 10 INFORMATION READILY AVAILABLE TO SUPPORT THEIR PRESCRIBING 11 DECISIONS.

12 (D) BEGINNING APRIL 1, 2011, THE DEPARTMENT, IN CONSULTATION 13 WITH THE MARYLAND BOARD OF PHYSICIANS AND THE STATE BOARD OF 14 PHARMACY AND SUBJECT TO THE AVAILABILITY OF FUNDS:

15(1)SHALL WORK WITH THE UNIVERSITY OF MARYLAND SCHOOL16OF PHARMACY TO DEVELOP, IMPLEMENT, AND PROMOTE THE PROGRAM; AND

17(2) MAY CONTRACT WITH THE UNIVERSITY OF MARYLAND18SCHOOL OF PHARMACY TO ADMINISTER THE PROGRAM.

(E) THE PROGRAM SHALL PROVIDE HEALTH CARE PROFESSIONALS
 WHO ARE AUTHORIZED BY LAW TO PRESCRIBE OR DISPENSE PRESCRIPTION
 DRUGS WITH INFORMATION AND EDUCATION:

22(1) ON THE COMPARATIVE EFFICACY, SAFETY, AND23COST-EFFECTIVENESS OF PRESCRIPTION DRUGS; AND

(2) PRIMARILY THROUGH IN-PERSON OUTREACH AND
 EDUCATION SESSIONS, ON A ONE-TO-ONE BASIS WHEN PRACTICABLE, IN THE
 WORKPLACE OF THE HEALTH CARE PROFESSIONALS.

(F) (1) THE PROGRAM SHALL PROVIDE THE INFORMATION AND
EDUCATION UNDER SUBSECTION (E) OF THIS SECTION TO HEALTH CARE
PROFESSIONALS WHO PARTICIPATE IN, CONTRACT WITH, OR ARE REIMBURSED
BY STATE HEALTH CARE PROGRAMS.

(2) THE PROGRAM MAY PROVIDE THE INFORMATION AND
 EDUCATION UNDER SUBSECTION (E) OF THIS SECTION TO OTHER HEALTH CARE
 PROFESSIONALS AS FUNDING PERMITS OR FOR A FEE.

1 (G) THE INFORMATIONAL AND EDUCATIONAL MATERIALS USED IN THE 2 PROGRAM:

3 (1) SHALL BE BASED ON A BALANCED AND COMPREHENSIVE
4 REVIEW OF EVIDENCE THAT IS ACCEPTED WITHIN THE PRACTICE OF MEDICINE,
5 INCLUDING SCIENTIFIC RESEARCH THAT CONFORMS TO THE GENERALLY
6 ACCEPTED STANDARDS OF EXPERIMENTAL DESIGN, DATA COLLECTION,
7 ANALYSIS, AND INTERPRETATION; AND

8 (2) SHALL AIM TO PROVIDE UNBIASED CONTINUING EDUCATION 9 ON THE COMPARATIVE EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF 10 PRESCRIPTION DRUGS.

(H) THE DEPARTMENT, WORKING WITH THE UNIVERSITY OF
 MARYLAND SCHOOL OF PHARMACY, SHALL DETERMINE, FOR INDIVIDUALS
 CONDUCTING OUTREACH AND EDUCATION SESSIONS:

14

(1) **MINIMUM CLINICAL AND EDUCATIONAL QUALIFICATIONS;**

15 (2) **REQUIRED TRAINING;**

16(3) A CODE OF CONDUCT GOVERNING INTERACTIONS WITH17HEALTH CARE PROFESSIONALS; AND

18 (4) CONFLICT OF INTEREST GUIDELINES.

19 (I) THE DEPARTMENT MAY ADOPT REGULATIONS TO CARRY OUT THE 20 REQUIREMENTS OF THIS SUBTITLE.

21 **21–2B–02.**

22 (A) THERE IS AN EVIDENCE-BASED PRESCRIBER EDUCATION AND 23 OUTREACH PROGRAM FUND.

24 (B) THE PURPOSE OF THE FUND IS TO SUPPORT THE OPERATION OF 25 THE PROGRAM.

26 (C) THE DEPARTMENT SHALL ADMINISTER THE FUND.

27 (D) (1) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT 28 SUBJECT TO § 7–302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.

1 (2) THE STATE TREASURER SHALL HOLD THE FUND 2 SEPARATELY, AND THE COMPTROLLER SHALL ACCOUNT FOR THE FUND. 3 **(E)** THE FUND CONSISTS OF: 4 FEES COLLECTED FROM PHARMACEUTICAL MANUFACTURERS (1) 5 AND LABELERS UNDER § 21–2B–03 OF THIS SUBTITLE; 6 (2) MONEY APPROPRIATED IN THE STATE BUDGET TO THE FUND; 7 AND 8 (3) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED 9 FOR THE BENEFIT OF THE FUND. 10 **(F)** THE FUND MAY BE USED ONLY FOR: 11 (1) PRESCRIBER INFORMATION, EDUCATION AND OUTREACH 12ACTIVITIES, AS PROVIDED UNDER § 21-2B-01 OF THIS SUBTITLE; AND 13 (2) **ADMINISTRATION OF THE PROGRAM.** 14 (G) (1) THE STATE TREASURER SHALL INVEST THE MONEY OF THE 15FUND IN THE SAME MANNER AS OTHER STATE MONEY MAY BE INVESTED. 16 (2) ANY INVESTMENT EARNINGS OF THE FUND SHALL BE 17 CREDITED TO THE GENERAL FUND OF THE STATE. 18 **(H)** EXPENDITURES FROM THE FUND MAY BE MADE ONLY IN 19 ACCORDANCE WITH THE STATE BUDGET. 20 21-2B-03. 21BEGINNING APRIL 1, 2010, AND ANNUALLY THEREAFTER, EACH (A) 22PHARMACEUTICAL MANUFACTURER AND LABELER DOING BUSINESS IN THE 23STATE SHALL PAY A FEE OF \$2,500 TO THE DEPARTMENT. 24 THE DEPARTMENT MAY REDUCE THE FEE TO BE PAID UNDER **(B)** 25SUBSECTION (A) OF THIS SECTION FOR A PHARMACEUTICAL MANUFACTURER 26 OR LABELER WHOSE VOLUME OF BUSINESS IN THE STATE JUSTIFIES A FEE 27**REDUCTION, AS DETERMINED BY THE DEPARTMENT.** 28THE DEPARTMENT SHALL DEPOSIT ALL FEES COLLECTED UNDER **(C)** 29 THIS SECTION IN THE FUND ESTABLISHED UNDER § 21-2B-02 OF THIS 30 SUBTITLE.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
 October 1, 2009.